Suppr超能文献

激活沉默信息调节因子:新一代癌症药物靶点的崛起。

Rejuvenating sirtuins: the rise of a new family of cancer drug targets.

机构信息

Room 221, Department of Internal Medicine, University of Genoa, V.le Benedetto XV 6, 16132 Genoa, Italy.

出版信息

Curr Pharm Des. 2013;19(4):614-23. doi: 10.2174/138161213804581954.

Abstract

Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.

摘要

Sirtuins 是一组 NAD+-依赖性酶,大约十年前被提出可以控制生物体的寿命。虽然 sirtuins 的这种作用目前存在争议,但越来越多的证据表明这些酶参与了许多生理过程和疾病状况,包括代谢、营养行为、昼夜节律,但也包括炎症和癌症。SIRT1、SIRT2、SIRT3、SIRT6 和 SIRT7 都与致癌作用有关,要么作为肿瘤抑制因子,要么作为促进癌症的蛋白质。在这里,我们回顾了寻找 sirtuin 抑制剂和激活剂来治疗癌症的生物学依据,以及鉴定它们的实验方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56bb/3549556/8b221166898f/CPD-19-614_F1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验